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MaNeurological events after transcatheter (TAVR) or surgical aortic valve replacement (SAVR) are potentially devastating
and associated with a poor prognosis. With technological improvements and increased operator experience, their
incidence is markedly declining, justifying the need for surrogate endpoints to be used in future comparative trials.
Moreover, imaging studies after TAVR and SAVR suggest that neurological events are mainly embolic in nature;
however, there is signiﬁcant discrepancy between imaging ﬁndings and clinically overt symptoms, raising the
possibility of more subtle subclinical cognitive decline. Different modalities have been used to assess both overt
and subclinical neurological events after SAVR and TAVR. The purpose of this report is to systematically review and
describe currently used imaging, functional, and neurocognitive testing modalities and to better understand how they
could be integrated in future prospective studies. (J Am Coll Cardiol 2014;64:1950–63) © 2014 by the American
College of Cardiology Foundation.T ranscatheter aortic valve replacement (TAVR)has emerged as a full-ﬂedged therapeuticalternative for patients with severe aortic
stenosis. After the publication of the PARTNER
(Placement of Aortic Transcatheter Valves) trial, the
main concern was the occurrence of post-procedural
stroke or transient ischemic attack (TIA), with re-
ported incidences ranging from 5.5% in high-risk
patients (Cohort A) to 6.7% in inoperable patients
(Cohort B) at 30 days (1,2). By comparison, the
30-day rate of stroke or TIA after surgical aortic
valve replacement (SAVR) was reported at 2.4% in
PARTNER Cohort A and 1.7% in the medical treat-
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Additionally, the recently published CoreValve High-
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AB BR E V I A T I O N S
AND ACRONYM S
CABG = coronary artery bypass
grafting
DW-MRI = diffusion-weighted
magnetic resonance imaging
HITS = high-intensity transient
signals
NE = neurological events
SAVR = surgical aortic valve
replacement
TAVR = transcatheter aortic
valve replacement
TCD = transcranial Doppler
transient ischemic attack
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1951advances, increased operator experience, and better
patient selection. Althoughmore deﬁnitive large-scale
prospective studies are needed, continued decreases
in NE rates might also be expected with the use of
neurological embolic protection devices (8). By
contrast, using detailed and systematic post-operative
neurological evaluation, a recently published registry
of nearly 200 patients undergoing SAVR demonstrated
a rate of 17% for clinically signiﬁcant stroke, higher
than previously reported (9). Together, these ﬁndings
underline the importance of standardized post-
procedural neurological evaluation and appropriate
imaging testing if fair and meaningful comparisons
between interventions are to be performed.
CLINICAL AND SUBCLINICAL NE. Several mecha-
nisms for the occurrence of post-procedural NE have
been suggested. Initial diffusion-weighted magnetic
resonance imaging (DW-MRI) reports showed multi-
ple and diffuse lesions appearing after TAVR, leading
to the currently accepted hypothesis of embolization
as the probable etiology (10,11). Among others, Van
Mieghem et al. (12) conﬁrmed the solid nature of
embolic debris captured during TAVR procedures
using a cerebral protection device.
Importantly, there is manifest discordance be-
tween the incidence of cerebral emboli and that of
clinically signiﬁcant events. Indeed, the majority of
patients display new, apparently asymptomatic, ce-
rebral lesions after TAVR. However, whether these
cerebral microinfarcts cause long-term cognitive and
behavioral changes is largely unknown. Whether
these changes can be predicted by periprocedural
imaging modalities, such as DW-MRI and transcranial
Doppler (TCD), is also unknown. Various neuro-
cognitive tests have also been utilized to describe
medium-term and long-term outcomes.
The purpose of this review is to explore how
TCD, DW-MRI, and neurocognitive tests have been
used to assess stroke and neurocognitive changes
in both TAVR and SAVR, and how they should be
integrated as surrogate endpoints of NE in future
research.
TRANSCRANIAL DOPPLER
DESCRIPTION. This test looks for high-intensity
“chirps” in the Doppler signal of an intracranial ar-
tery (usually the middle cerebral artery). Examples
are displayed in Figure 1. The tracings are obtained
with ultrasound transducers attached to a patient’s
head bitemporally over the preauricular transcranial
“window.”
SURGICAL AORTIC VALVE REPLACEMENT. A total of
22 reports investigating TCD in SAVR were publishedbetween 1994 and 2012 (Table 1) (13–34).
Although 1,732 patients were studied, only
165 underwent biological SAVR. Studies
report either the incidence or absolute count
of high-intensity transient signals (HITS) per
patient.
Hypotheses concerning the nature of HITS
detected by TCD include: 1) solid microemboli
of thrombotic origin; 2) cavitation or gaseous
bubbles; and 3) artifacts. Various algorithms
have been implemented in Doppler equip-
ment in order to help discriminate the nature
of the signals and to eliminate artifacts, but
their validity has never been conﬁrmed,
either histologically or pathologically (33).One of the main limitations of studies involving
TCD is heterogeneity in the timing of recording. In all
but 3 studies where TCD was done during surgery
(16,28,32), the reported time of recording ranged from
4 h to 12 years after SAVR, reﬂecting more acute,
subacute, and long-term prosthesis embolic poten-
tial, rather than procedural risk.
In one of the studies using TCD during surgery,
the use of an intra-aortic ﬁlter device to reduce
NE was compared with placebo in 24 patients (28).
Investigators found more HITS in patients who
received the ﬁlter (385.5 HITS) compared with those
who did not (99 HITS). There were no clinical
strokes or TIAs, and both DW-MRI and neuropsy-
chological studies were similar before and after
surgery in both groups. Electron microscopy of the
retrieved material from the ﬁlter showed that all but
1 particle were <1 mm, and 75% contained athero-
matous material, 25% contained platelet–ﬁbrin, and
25% contained thrombus.
Most importantly, NE were rare in these studies,
and there was no relationship between HITS and
occurrence of stroke or TIA (21,26,27,31). Keeping in
mind the small sample sizes, these studies may sug-
gest that, despite a signiﬁcant number of HITS, pa-
tients may experience no signiﬁcant clinical events
and display normal DW-MRI and neuropsychological
studies.
TRANSCATHETER AORTIC VALVE REPLACEMENT. A
total of 6 reports (5 peer-reviewed articles and 1
abstract) were published between 2011 and 2012
where TCD was used to evaluate NE after TAVR
(Table 1) (35–40). Studies were small, enrolling be-
tween 21 and 83 patients.
Contrary to most SAVR studies, in all of these
reports, TCD was done during the procedure,
allowing analysis of HITS during different phases of
aortic valve manipulation. All patients presented
HITS during TAVR. Interestingly, there seems to be
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CENTRAL ILLUSTRATION Imaging and Functional Assessment of NE After TAVR or SAVR
Neurological events (NE) after transcatheter aortic valve replacement (TAVR) or surgical aortic valve replacement (SAVR) are mainly due to
particle embolization during or soon after the procedure. Subclinical neurological events, in contrast to stroke or TIA, are frequent during TAVR
or SAVR procedures. Current modalities to detect and assess subclinical neurological events include transcranial Doppler, diffusion-weighted
MRI, and neurocognitive testing. HITS ¼ high-intensity transient signals; MRI ¼ magnetic resonance imaging; TIA ¼ transient ischemic attack.
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1952signiﬁcant variability in the number of recorded
HITS between studies, even when stratifying results
by prosthesis type and access site. For example,
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FIGURE 1 TCD Reading During TAVR
No high-intensity transient signals were observed at rest (A), whereas s
Reproduced with permission from Kahlert et al. (52). TAVR ¼ transcathe(Edwards Lifesciences, Irvine, California) generated
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ter aortic valve replacement; TCD ¼ transcranial Doppler.
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1953recordings, or artifact-elimination algorithms. The
procedure segments that yielded the most HITS
were valve positioning and deployment.
Clinical events were rare in all these studies, with
stroke incidence ranging from 0% to 4.5%, similar
to SAVR studies involving TCD assessment. Most
importantly, no relationship between HITS and NE
was established.
COMPARATIVE STUDIES: TAVR VERSUS SAVR. Two
abstracts compared TAVR and SAVR in terms of
HITS (Table 1) (41,42). In a nonrandomized study,
Alassar et al. (41) showed signiﬁcantly fewer HITS
during TAVR than SAVR (most HITS occurred com-
ing off cardiopulmonary bypass) in a total of
60 patients (p ¼ 0.04). There was 1 clinical stroke in
each group.
Similarly, Kempfert et al. (42) reported signiﬁ-
cantly fewer HITS in the transapical TAVR group
compared with the transfemoral TAVR and the SAVR
groups. Interestingly, this study compared TCD with
DW-MRI ﬁndings. Although transapical TAVR pa-
tients presented the fewest HITS, one-half presented
new DW-MRI lesions; this was true for only 29% of
SAVR patients. Despite the high rate of DW-MRI
ﬁndings, no signiﬁcant differences in neurocognitive
outcomes were found between groups using the Trail
Making, Pegboard, and verbal learning tests.
Table 2 summarizes the advantages and limitations
of TCD for assessment of neurological outcomes
after TAVR and SAVR.
DIFFUSION-WEIGHTED
MAGNETIC RESONANCE IMAGING
DESCRIPTION. DW-MRI allows diffusion of mole-
cules (mainly water) to be mapped in biological tis-
sues. When applied to the brain, locations of acute
ischemia, where the water diffusion rate is low,
appear brighter than surrounding tissues.
SURGICAL AORTIC VALVE REPLACEMENT. Three
reports were published between 2004 and 2006 using
DW-MRI as the main endpoint (Table 3) (43–45).
Although new DW-MRI lesions were found in 38% to
47% of patients undergoing SAVR, the stroke rate was
between 0% and 9%. Knipp et al. (44) reported and
compared DW-MRI ﬁndings with 11 neuropsycholog-
ical tests in 30 patients undergoing SAVR. Although
there were no clinical strokes, there was signiﬁcant
decline in 5 of 13 neurocognitive tests at 5 days, with
a return to baseline at 4 months. Interestingly, no
correlation was found between new lesions and
impaired neurocognitive function at 5 days. Finally,
Floyd et al. (45) reported no deﬁnitive correlation
between lesion size or number and stroke. None ofthe studies explored whether new DW-MRI lesions
persist over time.
TRANSCATHETER AORTIC VALVE REPLACEMENT. A
total of 7 reports (5 peer-reviewed articles, 2 ab-
stracts) using DW-MRI as an endpoint have been
published (Table 3) (10,46–51). Studies were relatively
small, enrolling between 12 and 61 TAVR patients. Of
note, the main issue with DW-MRI after TAVR is
the exclusion of at least one-third of patients in all
studies because of either post-procedural instability
or the need for a permanent pacemaker.
Observational studies showed that more than two-
thirds of patients undergoing TAVR present with new
DW-MRI lesions, mostly multiple and dispersed,
suggesting an embolic pattern (10,47,48,50–56). In
only 2 abstracts was the proportion of patients with
new lesions less elevated (46,49). Figure 2 displays
typical DW-MRI ﬁndings after TAVR.
Although most patients displayed new ischemic
lesions, clinical strokes were rare in these observa-
tional studies, with rates ranging from 0% to 6.5%.
Only 1 study established a relationship between MRI
lesions and NE: Fairbairn et al. (50) suggested that
stroke might be associated with a greater number and
volume of lesions. However, given that it is on the
basis of only 2 clinical events, this conclusion should
be treated with circumspection.
COMPARATIVE STUDIES: TAVR VERSUS SAVR. Five
studies compared TAVR patients with SAVR controls,
either concomitant or historical (Table 3) (52–56).
Because these were nonrandomized studies, there
were marked differences in patient age and baseline
characteristics (EuroSCORE), with SAVR patients be-
ing at signiﬁcantly lower risk. In all studies, more
TAVR patients showed new DW-MRI lesions than
SAVR patients. Lesions in TAVR patients were more
often larger in volume than in SAVR patients; how-
ever, clinical strokes were rare, ranging from 0% to
4.4% in TAVR patients and between 0% and 4.8% in
SAVR groups. No relationship between number or size
of MRI lesions and clinical events was made in any of
these comparative reports. In 2 studies where DW-
MRI was done again at 3 or 6 months, 80% of le-
sions showed no residual signal change in one (52)
and completely resolved in the other (56), with
either procedure.
In brief, after SAVR or TAVR, a signiﬁcant pro-
portion of patients develop presumably embolic
cerebral lesions, which may regress with time. No
signiﬁcant relationship has been established be-
tween these ﬁndings and clinical events. The pros
and cons of DW-MRI use in this setting are described
in Table 2.
TABLE 1 Selected Publications Reporting the Use of TCD in SAVR and TAVR
First Author
(Ref. #) Year n Procedure
Age
(yrs) Outcomes Timing
Duration of
TCD Reading
(Min) Main Findings
SAVR studies
Grosset et al.
(13)
1994 64 a) mAVR: 50
b) bAVR: 14
a) 62
b) 63
HITS incidence 1 week–12 yrs 2 min per site
(carotid,
vertebral)
a) 88% had HITS
b) 14% (p < 0.01)
More HITS in carotid artery vs.
vertebral
More HITS in patients with 2 vs. 1
prostheses
Müller et al.
(14)
1994 100 mAVR, mMVR,
mMVRþAVR
NA HITS incidence <3 weeks (n ¼ 50),
>3 months
(n ¼ 50)
10 66% had HITS at <3 weeks, 42% at
>3 months
Brækken et al.
(15)
1995 92 mAVR 64 HITS incidence 2–4 d (n ¼ 36), 1 yr
(n ¼ 34), 5 yrs
(n ¼ 22)
30 77.8% had HITS 2–4 d, 91.2% at 1 yr,
95.5% at 5 yrs
Georgiadis
et al. (16)
1996 19 mAVR (n ¼ 2), healthy
volunteers (n ¼ 5),
patients with
potential embolic
sources (n ¼ 12)
NA Total HITS count During AVR 30 862 HITS (2 patients undergoing
mAVR)
Nötzold et al.
(17)
1997 29 a) Ross procedure: 8
b) mAVR: 9
c) control: 12
a) 51
b) 67
c) 22
HITS incidence a) 18.8 weeks
b) 152.8 weeks
60 a) 2 of 8 had HITS
b) 9 of 9
c) 0 of 12
Georgiadis
et al. (18)
1997 123 mAVR, mMVR,
mMVRþAVR
63 HITS incidence 17 months 45 >48% had HITS
Kaps et al.
(19)
1997 5 mAVR 58–75 Median HITS
count
8 months–5 yrs 30 Median HITS count: 9 per 30 min
Lievense et al.
(20)
1998 60 a) mAVR: 20
b) Homograft AVR: 20
c) Control: 20
a) 59
b) 48
c) 40
HITS incidence,
total HITS
count
a) 4.3 yrs
b) 8.1 yrs
30 a) 16 of 20 had HITS
b) 8 of 20
c) 1
More HITS in mAVR (n ¼ 13) vs.
homograft (n ¼ 3)
Sliwka et al.
(21)
1998 580 a) mAVR: 515
b) bAVR: 65
62 Median HITS
count, HITS
incidence
15  1 month 30 a) 70.3% had HITS
b) 26.2%
Higher HITS count in mAVR (6 vs. 0)
Higher HITS count in patients with 2
prostheses vs. 1
11.4% had neurological event at a
median of 37  5 months
No difference in HITS counts or
incidence between those with and
thosewithout neurological events
Georgiadis
et al. (22)
1998 10 mAVR, mMVR,
mMVRþSAVR
38 Median HITS count
at CCA vs.
MCA/ACA
18  2 months 30 112 HITS at CCA; 30 HITS at
MCA/ACA
Geiser et al.
(23)
1998 52 a) mAVR, mMVR,
mMVRþSAVR: 26
b) Control: 26
a) 62
b) NA
Median HITS
count, HITS
incidence
5.2  4.6 yrs 30 a) 81% had HITS
b) 0%
Median HITS count: 24
Signiﬁcantly more HITS in patients
with previous neurological events
than those without
Milano et al.
(24)
1999 83 mAVR, mMVR,
mMVRþSAVR,
bAVR, homograft,
mitral valve repair
NA HITS incidence,
HITS incidence
rate
Discharge,
3 months, 1 yr
30 85% mechanical prosthesis had
HITS; 10% biological prosthesis;
0% homograft/mitral repair
55  79 HITS/h
Baumgartner
et al. (25)
2001 15 mAVR, mMVR,
mMVRþSAVR
52 Median HITS count Post-op 30 Median: 20 HITS
Stefani et al.
(26)
2002 47 mAVR, mMVR NA HITS incidence,
total HITS
count
$6 months 45 38.3% had HITS
Those with lower INR had more HITS
(p < 0.01)
No difference in HITS between AVR
and MVR
5 focal neurological deﬁcits>6months
in mAVR; no association with HITS
Koﬁdis et al.
(27)
2002 52 a) Sorin mAVR: 22
b) Tekna mAVR: 20
c) Control: 10
a) 58
b) 54
c) 52
HITS incidence
rate, HITS
incidence
Post-op NA a) 14 of 22 had HITS; 16.4  19
HITS/h; 5 TIA/PRIND
b) 15 of 20 had HITS; 14.4  24
HITS/h; 7 TIA/PRIND þ 1 stroke
c) 0 of 10 had HITS; 0; 0 events
No correlation between HITS and
clinical events
Continued on the next page
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TABLE 1 Continued
First Author
(Ref. #) Year n Procedure
Age
(yrs) Outcomes Timing
Duration of
TCD Reading
(Min) Main Findings
Eifert et al.
(28)
2003 24 CABG (n ¼ 17);
SAVR (n ¼ 4);
CABGþSAVR (n ¼ 3)
Aortic ﬁlter in 12 of 24
Filter: 64
No ﬁlter: 61
Total HITS count,
DW-MRI,
neuropsy,
electron
microscopy
TCD: during AVR,
others: pre-op,
5–7 d
NA More HITS with ﬁlter (385.5) than
without (99) (p ¼ NS)
All particles retrieved from ﬁlter
smaller than 1 mm, but 1 of
4.5 mm; 75% atheromatous
material, 25% platelet-ﬁbrin,
25% thrombus
DW-MRI: no new lesions post-op
No clinical strokes, no change in
cognitive performance
Laas et al.
(29)
2003 30 mAVR:
a) Bileaﬂet: 20
b) Tilting disc: 10
58–78 HITS incidence
rate
$9 months 30 a) 32–108 HITS/h
b) 0.2 HITS/h
Uekermann
et al. (30)
2005 40 mAVR 62 Median HITS
count, neuropsy
5.3 yrs 30 Patients divided into HITS-high and
HITS-low groups according to
median
HITS-high scored lower on verbal
memory and showed executive
deﬁcits
Patients showed verbal and visual
memory deﬁcits compared with
controls
Warnecke
et al. (31)
2006 150 mAVR 62 Total HITS count 3–36 months NA Linear association between valve size
and HITS count
No strokes, 8 TIAs with no
correlation with HITS or valve
size
Schönburg
et al. (32)
2006 41 SAVR
DBT in 22 of 41
DBT: 59
No DBT: 58
Total HITS count during AVR 66 DBT signiﬁcantly reduced absolute
number of HITS during CPB þ
crossclamp, but not after aorta
is unclamped
No strokes
Guerrieri
Wolf et al.
(33)
2008 60 a) mAVR: 30
b) bAVR: 30
a) 55
b) 71
HITS incidence,
discriminated
(solid vs. gaseous)
Pre-op, 5 d,
3 months
30 Pre-op: a) 6 of 30 had gaseous HITS;
b) 6 of 30
5 d: a) 29 of 30 had HITS, 24 of 29
solid; b) 21 of 30, 12 of 21 solid
3 months: a) 29 of 30 had HITS, 28 of
29 solid; b) 18 of 30 HITS, 4 of 18
solid
Al-Atassi
et al.
(34)
2012 56 bAVR 72 HITS incidence,
biomarkers (PFA,
P-selectin)
4 h, 1 month 30 At 4 h: a) 68% had HITS b) 82%
1 month: a) 46% had HITS; b) 43%
All p values >0.05
No strokes; no difference in
biomarkers between groups
Continued on the next page
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1955NEUROCOGNITIVE TESTING
DESCRIPTION. Neurocognitive tests are heteroge-
neous and meant to evaluate higher-order cerebral
functions such as memory, learning, attention, and
language skills. Some tests are speciﬁc to 1 func-
tion, whereas others are integrative. Simple tests
may be performed at the bedside by the clinician,
but more complex tests may require a neuropsy-
chologist’s expertise. A brief proﬁle of each neuro-
cognitive test described in this review is displayed
in Table 4.
SURGICAL AORTIC VALVE REPLACEMENT. A total of
6 studies report neurocognitive outcomes after SAVR
as their primary endpoint (Table 5) (57–62).An Austrian group published a series of 4 papers
between 2002 and 2012 using auditory evoked po-
tentials as the main neurocognitive outcome (58–61).
This highly reproducible test consists of objective
measurements related to information processing,
allowing quantiﬁcation of cognitive brain dysfunc-
tion. Their ﬁrst study showed impaired cognition at
7 days compared with baseline in 2 groups of 30
patients undergoing either biological SAVR or coro-
nary artery bypass grafting (CABG) (58). Interestingly,
the CABG group returned to baseline at 4 months, but
the SAVR group showed progressive cognitive
decline. The Mini-Mental State Examination and the
Trail Making Test showed no difference between
groups, indicating lower discrimination.
TABLE 1 Continued
First Author
(Ref. #) Year n Procedure
Age
(yrs) Outcomes Timing
Duration of
TCD Reading
(Min) Main Findings
TAVR studies
Brinkman et al.
(35)
2011 42 a) TF-TAVR: 21
b) TA-TAVR: 21
NA Total HITS count During TAVR NA Total HITS count : a) 674; b) 542
(p ¼ 0.1)
Valve-related manipulations
generated more HITS than
BAV-related manipulations
Drews et al.
(36)
2011 50 TA-TAVR (ES) 80 Total HITS count,
divided in HITS
and MES
During TAVR 122 min Total HITS count: 730  1,717,
detected in all patients
Total MES: 140  327, detected in all
patients; most of the MES were
recorded during valvuloplasty
and positioning of the prosthetic
valve in the aortic position
No clinical strokes
Szeto et al.
(37)
2011 28 a) TF-TAVR: 18 (ES)
b) TA-TAVR: 10 (ES)
a) 85
b) 81
Total HITS count During TAVR NA Total HITS count: a) 375; b) 440
(p ¼ 0.58)
Most HITS during wire manipulation
in the aortic arch and during
valve insertion
Erdoes et al.
(38)
2012 44 a) TF-TAVR: 32 (ES/CV)
b) TA-TAVR: 12 (ES)
a) 79
b) 74
Median HITS
count, neuropsy
During TAVR,
neuropsy:
1 dat, 4–6
days
75  18
a) 67
b) 83
Median HITS: 548
Most HITS during valve deployment,
regardless of access site or valve
type
More HITS with CV than ES (p¼ 0.024)
2 clinical strokes within 2 weeks, no
change on neuropsy score
Kahlert et al.
(39)
2012 83 a) TF-TAVR: 32 (CV)
b) TF-TAVR: 26 (ES)
c) TA-TAVR: 25 (ES)
a) 80
b) 83
c) 80
Total HITS count,
neuropsy
Pre-procedure,
during TAVR,
3 months
30 min
(pre-op,
3 months)
Total HITS count: 528.7
Most HITS during valve positioning
(ES > CV) and implantation
(CV > ES)
No difference in total HITS between
ES and CV, or between TF and TA
No HITS at baseline or at 3 months
Mean transaortic gradient is a
predictor of more HITS
2 clinical strokes total
Reinsfelt et al.
(40)
2012 21 TF-TAVR (CV) 81 Total HITS count,
biomarker (S100b)
During TAVR NA Total HITS count: 282 (mean)
Timing of HITS: 37% during
manipulation of the aortic arch/
root/valve by guidewires and
catheters, 22% after balloon
dilatation of the native valve,
41% during frame expansion of
the valve prosthesis
Positive correlation (r ¼ 0.68)
between HITS count and AUC of
biomarker
No clinical strokes
Comparative studies
Kempfert et al.
(42)
2010 121 a) TF-TAVR: 44 (CV)
b) TA-TAVR: 50 (ES)
c) SAVR: 27
a) 80
b) 82
c) 82
DW-MRI, total
HITS count,
neuropsy
NA NA Least HITS in TA group, TF and SAVR
had similar HITS
New MRI lesions: a) 59%;
b) 50%; c) 29%
No difference in neurocognitive
outcomes between groups
Strokes: a) 1 of 44; b) 0 of 50;
c) 1 of 27
Alassar et al.
(41)
2013 60 a) TAVR: 46
b) SAVR: 14
NA Median HITS
count
a) During TAVR
b) During SAVR
NA Median HITS: a) 168; b) 244 (p¼ 0.04)
During TAVR, most HITS during valve
implantation
During SAVR, most HITS during
coming off CPB
Strokes: a) 1 of 46; b) 1 of 14
Values are mean unless otherwise indicated.
ACA ¼ anterior cerebral artery; AUC ¼ area under the curve; BAV ¼ balloon aortic valvuloplasty; bAVR ¼ surgical aortic valve replacement with bioprosthesis; CABG ¼ coronary artery bypass graft; CCA ¼
common carotid artery; CPB ¼ cardiopulmonary bypass; CV ¼ Medtronic CoreValve; DBT ¼ dynamic bubble trap; DW-MRI ¼ diffusion-weighted magnetic resonance imaging; ES ¼ Edwards SAPIEN; HITS ¼
high-intensity transient signals; INR ¼ international normalized ratio; mAVR ¼ surgical aortic valve replacement with mechanical prosthesis; MCA ¼ middle cerebral artery; MES ¼ microembolic signals;
mMVR ¼ surgical mitral valve replacement using mechanical prosthesis; NA ¼ not available; neuropsy ¼ neuropsychological testing; PFA ¼ platelet function analysis; PRIND ¼ prolonged reversible ischemic
neurological deﬁcit; SAVR¼ surgical aortic valve replacement; TA¼ transapical; TAVR¼ transcatheter aortic valve replacement; TCD¼ transcranial Doppler; TF¼ transfemoral; TIA¼ transient ischemic attack.
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TABLE 2 Advantages and Disadvantages of Neurological Testing Modalities
Used to Assess Neurological Outcomes After SAVR and TAVR
Modality Advantages Disadvantages
Transcranial
Doppler
Provides live information allowing
the identiﬁcation of potentially
problematic segments of the
procedure
Has been used extensively in the
surgical literature
Labor intensive
Data analysis method has not been
standardized
Artifacts may increase variability
between patients
No consistent relationship has
been shown between high-
intensity transient signals and
overt or subclinical events
Diffusion-weighted
magnetic
resonance
imaging
Easy and relatively inexpensive
Provides precise anatomical
localization of neurological
lesions
Can be repeated in time to evaluate
lesion evolution
Many patients excluded because
of instability or pacemaker
No consistent relationship has
been shown between
diffusion-weighted magnetic
resonance imaging lesions and
overt or subclinical events
Neurocognitive
tests
Results represent the true clinical
outcome of interest
Can be repeated in time to evaluate
deﬁcit evolution
Results are highly dependent on
test selection
Labor intensive
Costly if tests are performed by
trained professionals
Abbreviations as in Table 1.
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1957Their next study compared mechanical versus
biological SAVR in 82 patients (59). Cognitive dys-
function was found at 7 days in both groups, but the
mechanical SAVR group returned to normal at 4
months, whereas the biological SAVR group showed
progressive decline. Return to baseline values in
mechanical SAVR patients at 3 years was conﬁrmed in
another of their studies (60).
In brief, these ﬁndings suggest that auditory
evoked potential testing may be a more reﬁned tool to
detect subtle cognitive decline after SAVR. Reasons
for the decline in patients undergoing biological
SAVR compared to mechanical SAVR remain to be
explored, but may relate to the age of patients or
to the presence of vascular disease and other
comorbidities.
TRANSCATHETER AORTIC VALVE REPLACEMENT.
Only 1 study and 1 abstract using neurocognitive tests
as their primary endpoint in TAVR patients were pub-
lished (Table 5) (63,64). These studies are larger, more
recent, and have longer clinical follow-ups than pre-
viously mentioned studies using imaging modalities.
Ghanem et al. (63) followed 111 patients for
at least 1 year after TAVR. Patients underwent
the Repeatable Battery for the Assessment of Neuro-
psychological Status (RBANS) at 3 days, 4 months, 1
year, and 2 years after the procedure. DW-MRI was
also done at 3 days. Again, although nearly two-thirds
of patients showed new cerebral lesions on DW-MRI,
there were no early clinical strokes. The Repeatable
Battery for the Assessment of Neuropsychological
Status showed new-onset cognitive dysfunction at
3 days in 6 patients, which persisted at 3 months
or more in 3 patients. Most importantly, cerebral
embolism detected by DW-MRI was not a predictor of
cognitive dysfunction in this study.
The relatively low incidence of cognitive decline
in this study has been criticized (65). Deterioration
of cognition may be underestimated because of
reliance on a global score after an injury that likely
results in patchy deﬁcits, and because of a ﬂoor
effect (i.e., little room for deterioration as patients
are already within impairment range at baseline),
among others. These deﬁcits may be palliated by
tests assessing coordinated integration of multiple
cortical regions.
COMPARATIVE STUDIES: TAVR VERSUS SAVR. Two
studies compared SAVR with TAVR in terms of neu-
rocognitive function (Table 5) (66,67). The ﬁrst used
the Syndrom Kurz Test and the Alzheimer’s Disease
Assessment Scale at 3 days after the index procedure
(66). Because this study was nonrandomized, patients
undergoing TAVR were signiﬁcantly older and had asigniﬁcantly higher EuroSCORE than those under-
going SAVR. Results showed signiﬁcant cognitive
decline in both groups at 3 days, with no difference
between groups, but a trend in favor of TAVR (p ¼ 0.1).
Knipp et al. (67) reported a high incidence of
cognitive decline in their TAVR group, using inte-
grative tests. At discharge (mean 10.7 days), 4 of 22
patients (18%) presented cognitive dysfunction, and 2
still had cognitive decline at 3 months. More than half
of patients had new DW-MRI lesions, but there was no
relationship between MRI ﬁndings and cognitive
dysfunction. A nonrandomized control group of SAVR
patients showed that close to one-half exhibited
cognitive dysfunction at discharge that completely
resolved by 3 months.
In summary, cognitive decline seems to occur
after TAVR, but its incidence varies according to
the clinical tool used to assess its presence. Al-
though integrative tests may represent the best
way to assess cognitive decline in this population,
auditory evoked potentials, which made their mark
in SAVR, were not used in any of the TAVR studies
and may be an interesting avenue of future re-
search. The strengths and weaknesses of neuroco-
gnitive testing in TAVR and SAVR are presented
in Table 2.
LIMITATIONS OF THE CURRENT LITERATURE,
AND FUTURE PERSPECTIVES
Although robust deﬁnitions were proposed for clini-
cally signiﬁcant NE (68), proper diagnosis requires
TABLE 3 Selected Publications Reporting the Use of DW-MRI in SAVR and TAVR
First Author
(Ref. #) Year n Procedure
Age
(yrs) Outcomes Timing Main Findings
SAVR studies
Stolz et al. (43) 2004 37 a) mAVR: 24
b) bAVR: 12
66 New DW-MRI lesion
incidence, biomarkers
(S100b, NSE)
Pre-op, 1–6 days New MRI lesions in 14 of 37; 11 of 14 with >1 lesion
3 strokes, all in patients with lesions
No association between biomarkers and DW-MRI lesions
Knipp et al. (44) 2005 30 SAVR (n ¼ 24);
MVR (n ¼ 2);
SAVRþMVR (n ¼ 2);
AVRþMV repair (n ¼ 2)
65 New DW-MRI lesion
incidence, neuropsy
Pre-op, 5 days,
4 months
New MRI lesions in 14 of 30, 10 of 14 with >1 lesions
No clinical strokes, 1 clinically silent cerebellar infarct
Decline in 5 of 13 neurocognitive tests at 5 days, return
to baseline at 4 months
No correlation between new lesions and impaired
neurocognitive function at 5 days
Floyd et al. (45) 2006 34 a) SAVR: 6
b) SAVR þ other: 9
c) MVR: 2
d) CABG: 13
e) MVRþCABG: 4
67 New DW-MRI lesion
incidence
Pre-op, 6  2 days New MRI lesions: a) 2 of 6; b) 4 of 9; c) 0 of 2; d) 0 of 13;
e) 0 of 4
3 clinical strokes: 2 in patients with lesions, 1 with no
lesion
No deﬁnitive correlation between lesion size/number
and stroke
Pre-op white matter lesion burden may predict new
post-op lesion
TAVR studies
Gasparetto et al.
(46)
2010 29 TF-TAVR: 26 (CV);
3 (ES)
NA New DW-MRI lesion
incidence
Pre-TAVR, 3 days 20 of 29 had chronic asymptomatic lesions at baseline
17 of 29 underwent DW-MRI at 3 days
4 of 17 had new lesions, mostly multiple and dispersed
No neurological impairment in 29 of 29
Ghanem et al.
(10)
2010 30 TAVR: CV 79 New DW-MRI lesion
incidence,
biomarker (NSE)
Pre-TAVR, #3 days,
3 months
22 of 30 underwent DW-MRI
16 of 22 had new lesions, mostly multiple and dispersed
3 of 30 had a neurological event, 1 of which was
permanent
Biomarker did not correlate with new DW-MRI lesions
Maier et al. (47) 2010 46 TF-TAVR: CV 81 New DW-MRI lesion
incidence
Pre-TAVR, #6 days 25 of 46 underwent DW-MRI
23 of 25 had new lesions, mostly multiple
Strokes: 0 of 46
Rodés-Cabau
et al. (48)
2011 60 a) TF-TAVR: 29 (ES)
b) TA-TAVR: 31 (ES)
a) 84
b) 81
New DW-MRI lesion
incidence
Pre-TAVR, #6 days New MRI lesions: 41 of 60, lesions mostly multiple and
dispersed
No difference between TF and TA in lesion number and
size
Stroke at 24 h: a) 1 of 29; b) 1 of 31
Eder et al. (49) 2012 12 TAVR: CV 84 New DW-MRI lesion
incidence, geriatric
assessment
Pre-TAVR, #1yr New lesions in 2of 12, clinically silent, not related to
change in geriatric assessment
1 of 12 deteriorated, 1 of 12 improved on geriatric
assessment at 1 yr
Fairbairn et al.
(50)
2012 31 TAVR: CV 81 New DW-MRI lesion
incidence, QoL
scores
DW-MRI: pre-TAVR,
5 days
QoL: pre-TAVR,
30 days
New MRI lesions: 24 of 31, lesions mostly multiple and
dispersed
Strokes: 2 of 31; stroke associated with greater number
and volume of lesions
Improvement in SF-12 physical; no change in SF-12
mental, EQ-5D, Visual Analog Scale
Ghanem et al.
(51)
2013 61 TAVR: CV 80 New DW-MRI lesion
incidence, biomarker
(NSE), self-sufﬁciency,
1-yr survival
Pre-TAVR, 3 days New MRI lesions: 28 of 39
Neurologic deﬁcit: 4 of 61
Incidence of NSE increase: 29 of 59
Plasma levels of NSE and new MRI lesions not related to
self-sufﬁciency or survival at 1 yr
Continued on the next page
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1958systematic pre-procedural and post-procedural ex-
pert neurological assessment. This is often lacking in
published studies and is impractical to implement
prospectively in all clinical settings. More impor-
tantly, the declining rate of clinically detectable
events makes any comparison, at least for future
randomized trials (SAVR vs. TAVR, TAVR vs. TAVR),
challenging.
Conversely, no real imaging and functional stan-
dardization of endpoints exists for the frequent, butmost often subclinical, neurocognitive changes that
may result from embolic events during SAVR or
TAVR. It remains unclear whether TCD and DW-
MRI are adequate surrogate endpoints for either
overt or subclinical NE. Although TCD does seem to
report cerebral embolic events and has the advan-
tage of showing these “live” during the procedure,
there is no ﬁrm relationship between HITS and
clinical events. Another important issue for future
comparative trials is that mechanical prostheses
TABLE 3 Continued
First Author
(Ref. #) Year n Procedure
Age
(yrs) Outcomes Timing Main Findings
Comparative studies
Kahlert et al.
(52)
2010 53 a) TAVR: 10 (CV);
22 (ES)
b) Historical control:
21 (SAVR)
a) 80
b) 67
New DW-MRI lesion
incidence, neuropsy
(MMSE)
Pre-TAVR, 3.4 days,
3 months
New DW-MRI lesions: a) 27 of 32, lesions mostly
multiple and dispersed; b) 10 of 21 (p ¼ 0.016)
Smaller volume of TAVR lesions than SAVR lesions
(p < 0.001)
No residual signal change at 3 months in 80% of lesions
In-hospital stroke: a) 0 of 32; b) 1 of 21
MMSE unchanged at 3 months in TAVR group
Astarci et al.
(53)
2011 48 a) TF-TAVR: 21 (ES)
b) TA-TAVR: 14 (ES)
c) SAVR: 13
a) 86
b) 83
c) 76
New DW-MRI
lesion incidence
Pre-TAVR, 2 days New MRI lesions: a) 19 of 21; b) 13 of 14; c) 1 of 13
In groups a) and b), lesions mostly multiple (mean
number of lesions ¼ 6), in group c) 1 new lesion
(p < 0.05)
Strokes: a) 0 of 21; b) 0 of 14; c) 0 of 13
Ensminger et al.
(54)
2012 92 a) TAVR: 48
b) SAVR: 44
a) 81
b) 78
New DW-MRI lesion
incidence, cerebral
microbleeds
Pre-TAVR, <6 days New MRI lesions: a) 30 of 48; b) 19 of 44
Strokes: a) 1 of 48; b) 0 of 44
Microbleeds: a) 6 of 48; b) 28 of 44
Uddin et al. (56) 2013 66 a) TAVR: 45
b) SAVR: 21
a) 80
b) 69
New DW-MRI lesion
incidence
Pre-TAVR, <7 days,
6 months
New MRI lesions: a) 37 of 45; b) 10 of 21; higher lesion
volume in a) than b)
Strokes: a) 2 of 45; b) 0 of 21
At 6 months: New microinfarct: a) 1 of 17; b) 1 of 18,
both subclinical; all previously detected lesions had
completely resolved
Astarci et al.
(55)
2013 77 a) TF-TAVR: 26 (ES)
b) TA-TAVR: 18 (ES)
c) BAV: 11
d) SAVR: 22
a) 86
b) 83
c) 83
d) 78
New DW-MRI lesion
incidence
Pre-TAVR, #4 days New MRI lesions: a) 24 of 26; b) 17 of 18; c) 3 of 11;
d) 6 of 22; a) and b) vs. c) and d): p < 0.0001
More lesions and larger lesions in a) and b) vs. c) and d)
(p < 0.0001)
Strokes: a) 0 of 26; b) 1 of 18; c) 0 of 11; d) 0 of 22
Values are mean unless otherwise speciﬁed.
MMSE ¼ Mini-Mental State Examination; NSE ¼ neuron-speciﬁc enolase; QoL ¼ quality of life; SF-12 ¼ 12-item Short-Form Questionnaire; other abbreviations as in Table 1.
FIGURE 2 DW-MRI Findings After TAVR
Post-interventional diffusion-weighted magnetic resonance imaging (DW-MRI) of an
82-year-old female patient after successful transcatheter aortic valve replacement
displaying 1 large (650 mm3) and 2 smaller foci of restricted diffusion in the right lower
cerebellar hemisphere (A) and multiple small foci dispersed in different territories
(A and B). Reproduced with permission from Kahlert et al. (52).
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1959consistently generate more HITS than biological
prostheses, potentially creating an uneven playing
ﬁeld for comparison between SAVR and TAVR in a
low-risk population where mechanical prostheses
are more likely to be chosen (Central Illustration).
By contrast, DW-MRI provides a more objective
assessment of lesions after TAVR or SAVR. It is
less labor-intensive and less costly than TCD or
neurocognitive testing, and has the advantage of
being repeatable to assess the evolution of lesions.
However, although pathophysiologically plausible,
it is unclear whether DW-MRI lesions translate
into overt NE or cognitive dysfunction (Central
Illustration).
Neurocognitive tests have the advantage of re-
presenting true clinical neurological decline; how-
ever, the incidence varies widely according to the
type of test. Auditory evoked potential testing rep-
resents an interesting integrative test that remains
objective, but has not yet been used in TAVR pa-
tients. Psychometric tests seem less useful to detect
subtle cognitive decline and may be biased by
long performance times, visual requirements (espe-
cially in elderly populations), and patient education
levels. Finally, these tests can be fairly costly andtime-consuming when executed by dedicated pro-
fessionals (Central Illustration).
The lack of research comparing same-risk pop-
ulations, especially lower-risk ones, is another
TABLE 4 Neurocognitive Tests
Test (Ref. #) Description Cognitive Functions Tested Advantages Disadvantages
Test Battery for Attention
Performance (TAP) (28,44)
Computer software Attention No training required License purchase; limited
assessment of cognitive
function
Wechsler Adult Intelligence
Scale (30)
IQ test (paper/software) Intelligence No training required Tests intelligence; not cognitive
deﬁcits
Trail Making Test
(30,42,44,57–59)
Patient must connect circles
respecting a certain sequence
Visual attention; task switching;
motor skills
No training required;
inexpensive
Limited assessment of cognitive
function
Purdue Pegboard Test (42) Pin placement test Manual dexterity No training required;
inexpensive
Limited assessment of cognitive
function
Confusion Assessment Method
(38)
Subjective assessment by health
professional
Presence of delirium No training required;
inexpensive
Subjective; cognitive deﬁcits not
speciﬁcally tested
Mini-Mental State Examination
(MMSE) (39,52,58,59,63,67)
Widely used test for cognitive
impairment
Orientation; attention; memory;
language; complex commands;
visual construction; calculation
No training required;
inexpensive;
integrative test
Poor sensitivity
Montreal Cognitive Assessment
(MoCA) (39,64)
Test for mild cognitive impairment Visuospatial; executive functions;
language; memory; attention;
abstraction; orientation
No training required;
inexpensive;
integrative test
Poor sensitivity
Verbal Learning Test (wordlist
test) (44,67)
Patient must memorize new words Verbal memory Inexpensive Limited assessment of cognitive
function
Digit span subtest of Wechsler
Adult Intelligence Scale (44,67)
Patient must repeat series of
numbers
Attention; short-term memory;
working memory
No training required;
inexpensive
Limited assessment of
cognitive function; part of
a test battery
Corsi block-tapping test (44) Patient must repeat a sequence of
tapping identical blocks
Short-term memory; working
memory
Inexpensive Administered by
neuropsychologist; part of
a test battery
P300 auditory evoked potential
(58–61)
Assessment of brain responses as
patient is instructed to count
occurrences of a speciﬁc sound
Stimulus evaluation; decision
making
Good sensitivity Administered by a neurologist/
neuropsychologist; resource
intensive
Cognitive Failures Questionnaire
(62)
Patient must answer a 25-item
questionnaire
Perception; memory; motor
function
No training required;
inexpensive
Subjective
Digit Cancellation Test (62) Patient must cross out identical
numbers
Attention Inexpensive Administered by
neuropsychologist; poor
discrimination; part of a test
battery
Regensburg Word Fluency Test
(verbal ﬂuency test) (62,67)
Patient must generate words
starting with given letter
Verbal ﬂuency Inexpensive Administered by
neuropsychologist; poor
discrimination; part of a test
battery
Non-verbal learning test (62) Patient must recognize symbols Visual memory Inexpensive Administered by
neuropsychologist; part of a test
battery
Repeatable Battery for the
Assessment of
Neuropsychological Status
(RBANS) (63)
Battery containing 12 subtests Language; attention; visual and
constructional skills; immediate
memory; delayed memory
Integrative test Administered by
neuropsychologist
Syndrom Kurz Test and
Alzheimer’s Disease Assessment
Scale (subtests) (62,66)
Battery containing 6 subtests Working memory (visual/verbal);
language; attention; delayed
memory
Integrative test Administered by
neuropsychologist
Lawton Instrumental
Activities of Daily Living Scale
(IADL) (63)
Questionnaire containing 8
subscales
Independent living skills No training required;
inexpensive
Cognitive deﬁcits not
speciﬁcally tested
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studies become more common, insight will be gained
concerning the strengths and limitations of each
neurological testing modality according to the studied
population. That being said, assessment of neurolog-
ical complications after carotid endarterectomy or
stenting faced similar challenges and is still a matter
of debate. Although microembolization and new
lesions are frequently detected, clinically signiﬁcantNE are rare. DW-MRI, with quantiﬁcation of number
and size of lesions, better correlated with clinical
events than TCD. Neurocognitive testing was more
speciﬁc, but requires considerable resources (69).
In conclusion, given their increased sensitivity and
relative ease of administration, and to gain further
insight into the occurrence of NE, we believe that
both TCD and DW-MRI should be used as effective
surrogate endpoints for NE. When possible, they
TABLE 5 Selected Publications Reporting Use of Neurocognitive Testing in SAVR and TAVR
First Author
(Ref. #) Year n Procedure
Age
(yrs) Outcome Measure
Outcome Measure
Timing Main Findings
SAVR studies
Nussmeler
et al.
(57)
1986 182 Valve replacement or
repair, aneurysm
resection, VSD closure
a) 89 received thio-
pental during CPB
b) 93 received stan-
dard anesthesia
a) 57
b) 55
Neuropsychiatric
abnormalities incidence
(orientation, affect,
ideation, memory (recent
and remote), Trail Making
Test, neurological exam)
24 h, 10 days Neuropsychiatric abnormalities at 24 h: a) 5.6%;
b) 8.6%
Neuropsychiatric abnormalities at 10 d: a) 0%;
b) 7.5%
Predictors of events: AVR, valvular calciﬁcations,
longer CPB, age $60 yrs
Zimpferetal.
(58)
2002 60 a) bAVR: 30
b) CABG: 30
a) 70
b) 70
P300 auditory evoked
potentials, MMSE, Trail
Making Test A
Pre-op, 7 days,
4 months
Impaired P300 at 7 d compared with pre-op in both
groups (p < 0.05, no difference between groups)
Return to normal of P300 at 4 months in group b);
decline in P300 at 4 months in group a) (p< 0.05
between groups)
MMSE and trail test: no difference between groups
Strokes: a) 0 of 30; b) 0 of 30
Zimpferetal.
(59)
2003 82 a) bAVR: 53
b) mAVR: 29
a) 73
b) 58
P300 auditory evoked
potentials, MMSE, Trail
Making Test A
Pre-op, 7 days,
4 months
Impaired P300 at 7 d compared with pre-op in both
groups (p < 0.05, no difference between groups)
Return to normal of P300 at 4 months in group b);
decline in P300 at 4 months in group a) (p< 0.05
between groups)
MMSE and Trail Making Test: no difference between
groups
Strokes: a) 1 of 30; b) 0 of 30
Zimpferetal.
(60)
2006 60 a) mAVR: 32
b) control: 28
a) 51
b) 51
P300 auditory evoked
potentials
Pre-op, 7 days,
4 months, 3 yrs
Impaired P300 at 7 d compared to pre-op in group a);
no difference at 7 d in control
Return to pre-op values at 4 months and 3 yrs
Strokes: a) 0 of 32; b) 0 of 28
Fakin et al.
(61)
2012 60 bAVR: mild
hypothermic CPB
(n ¼ 30); normothermic
CPB (n ¼ 30)
a) 68
b) 66
P300 auditory evoked
potentials, MMSE, Trail
Making Test A
Pre-op, 7 days,
4 months
Impaired P300 at 7 d and at 4 months in both groups
MMSE and Trail Making Test: no difference between
groups
Strokes: 0 of 60
Schwarz
et al.
(62)
2013 82 bAVR (67); mAVR (15) 69 Cognitive Failure
Questionnaire assessed
by family members,
neuropsy
Pre-op, 3 months Decline in all declarative memory function tests
(p values <0.001–0.033)
No change in Cognitive Failure Questionnaire
TAVR studies
Ghanem
et al.
(63)
2013 111 TAVR: 95 (CV); 16 (ES)
Embolic protection
device in 20
80 RBANS, MMSE, frailty,
QoL, IADL, mood, new
DW-MRI lesion incidence
Pre-TAVR, 3 days,
3 months, 1 yr,
2 yrs (MRI only
pre-op and 3 days)
Cognitive dysfunction at 3 d in 6 of 111 patients,
persisting in 3 of 6 at follow-up
Late-onset cognitive dysfunction (3 months, 1 yr,
2 yrs) in 4 of 111
DW-MRI done in 56 of 111; new DW-MRI lesions: 36
of 56
Age-predicted cognitive decline; new MRI lesions and
embolic protection devices unrelated to cognitive
decline
Strokes: 1 of 111 (at 8 months)
Pelletier
et al.
(64)
2013 47 TAVR (ES) 81 Montreal Cognitive
Assessment (MoCA)
Pre-TAVR, 6 months No change in MOCA score at 6 months
Comparative studies
Holinski
et al.
(66)
2013 100 a) SAVR: bAVR
(n ¼ 46); mAVR
(n ¼ 4)
b) TF-TAVR: 50
a) 69
b) 80
6 scales from Syndrom
Kurz Test and Alzheimer’s
Disease Assessment Scale
Pre-TAVR, 3 days Signiﬁcant cognitive decline at 3 d in both groups
(p ¼ 0.1 between groups, trend in favor of TAVR)
Knipp et al.
(67)
2013 64 a) TA-TAVR: 27 (ES)
b) SAVR: 37
a) 82
b) 68
Digit span test, wordlist
test, verbal ﬂuency test,
MMSE, new DW-MRI
lesion incidence
Pre-TAVR, pre-
discharge (10.7 days),
3 months
Cognitive decline at discharge: a) 4 of 22, persistent
in 2 of 4 at 3 months; b) 17 of 37, persistent in
0 of 17 at 3 months
New-onset cognitive decline at 3 months: a) 3 of 18;
b) 2 of 34
New MRI lesions: a) 7 of 12, lesions mostly multiple
and dispersed; b) 12 of 35, lesions mostly multiple
and dispersed
No relationship between presence of MRI lesions and
cognitive dysfunction
Strokes: a) 1 of 27 (fatal); b) 1 of 37 (minor)
Values are mean unless otherwise speciﬁed.
IADL ¼ Instrumental Activities of Daily Living; VSD ¼ ventricular septal defect; other abbreviations as in Tables 1 and 3.
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1962should be paired with appropriate neurological
testing to detect subtler (but very important) neuro-
cognitive decline post-TAVR or post-SAVR. Future
research should focus on integrating imaging and
neurocognitive testing to better identify future pre-
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